Payment overview · 2025
General Payments
$285.55
4 reported records · 3 companies
Healthcare provider profile · identity verified
Mark Allen Sanders, DO
Allopathic & Osteopathic Physicians|Family Medicine · FORT WORTH, TX · NPI 1770544389
Verified facts
What the public records show
CMS Open Payments records show Mark Allen Sanders, DO received $285.55 in general payments during 2025 across 4 reported records.
Stryker Corporation accounted for 82.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 5 associated products.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 61 claims for Myrbetriq by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 292 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Stryker Corporation | Unresolved — no canonical attribution shown | $234.50 | 82.1% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $28.53 | 10.0% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $22.52 | 7.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $285.55 | 4 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| INFINITY ADAPTIS Normalized: infinity adaptis |
Device | Stryker Corporation | $171.22 | 1 | 2025 |
Source payment records
|
|||||
| TRIATHLON Normalized: triathlon |
Device | Stryker Corporation | $63.28 | 1 | 2025 |
Source payment records
|
|||||
| INLYTA Normalized: inlyta |
Drug | PFIZER INC. | $28.53 | 1 | 2025 |
Source payment records
|
|||||
| PADCEV Normalized: padcev |
Biological | PFIZER INC. | $28.53 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $22.52 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
61 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
292 | 45 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 756 | 116 |
| Atorvastatin Calcium | Atorvastatin Calcium | 618 | 92 |
| Trazodone Hcl | Trazodone Hcl | 507 | 71 |
| Donepezil Hcl | Donepezil Hcl | 462 | 68 |
| Furosemide | Furosemide | 451 | 77 |
| Quetiapine Fumarate | Quetiapine Fumarate | 442 | 63 |
| Sertraline Hcl | Sertraline Hcl | 438 | 64 |
| Amlodipine Besylate | Amlodipine Besylate | 404 | 70 |
| Gabapentin | Gabapentin | 358 | 65 |
| Pantoprazole Sodium | Pantoprazole Sodium | 338 | 55 |
| Losartan Potassium | Losartan Potassium | 337 | 56 |
| Metoprolol Succinate | Metoprolol Succinate | 331 | 52 |
| Potassium Chloride | Potassium Chloride | 323 | 57 |
| Divalproex Sodium | Divalproex Sodium | 313 | 53 |
| Lisinopril | Lisinopril | 301 | 53 |
| Eliquis | Apixaban | 292 | 45 |
| Metoprolol Tartrate | Metoprolol Tartrate | 276 | 37 |
| Memantine Hcl | Memantine Hcl | 258 | 42 |
| Lorazepam | Lorazepam | 257 | 49 |
| Carvedilol | Carvedilol | 252 | 40 |
| Escitalopram Oxalate | Escitalopram Oxalate | 246 | 34 |
| Tamsulosin Hcl | Tamsulosin Hcl | 245 | 48 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 205 | 31 |
| Omeprazole | Omeprazole | 180 | 31 |
| Buspirone Hcl | Buspirone Hcl | 170 | 30 |
| Clopidogrel | Clopidogrel Bisulfate | 163 | 28 |
| Metformin Hcl | Metformin Hcl | 163 | 31 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 156 | 108 |
| Mirtazapine | Mirtazapine | 153 | 26 |
| Risperidone | Risperidone | 141 | 29 |
| Montelukast Sodium | Montelukast Sodium | 132 | 23 |
| Duloxetine Hcl | Duloxetine Hcl | 128 | 18 |
| Famotidine | Famotidine | 127 | 20 |
| Levetiracetam | Levetiracetam | 121 | 14 |
| Simvastatin | Simvastatin | 120 | 21 |
| Hydrochlorothiazide | Hydrochlorothiazide | 117 | 16 |
| Tramadol Hcl | Tramadol Hcl | 116 | 32 |
| Xarelto | Rivaroxaban | 106 | 13 |
| Spironolactone | Spironolactone | 96 | 16 |
| Alprazolam | Alprazolam | 90 | 21 |
| Atenolol | Atenolol | 89 | suppressed |
| Latanoprost | Latanoprost | 87 | 21 |
| Sucralfate | Sucralfate | 87 | 14 |
| Pravastatin Sodium | Pravastatin Sodium | 86 | 19 |
| Meloxicam | Meloxicam | 85 | 18 |
| Citalopram Hbr | Citalopram Hydrobromide | 83 | 13 |
| Olanzapine | Olanzapine | 82 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 81 | 14 |
| Allopurinol | Allopurinol | 78 | 14 |
| Fluticasone Propionate | Fluticasone Propionate | 71 | 25 |
| Divalproex Sodium Er | Divalproex Sodium | 69 | 17 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 68 | 16 |
| Hydralazine Hcl | Hydralazine Hcl | 65 | 12 |
| Myrbetriq | Mirabegron | 61 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 58 | 11 |
| Ropinirole Hcl | Ropinirole Hcl | 58 | 11 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 56 | suppressed |
| Finasteride | Finasteride | 53 | 14 |
| Oxybutynin Chloride | Oxybutynin Chloride | 52 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 51 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 51 | suppressed |
| Clonazepam | Clonazepam | 50 | suppressed |
| Glimepiride | Glimepiride | 49 | suppressed |
| Cefdinir | Cefdinir | 48 | 39 |
| Haloperidol | Haloperidol | 48 | 11 |
| Nifedipine Er | Nifedipine | 48 | suppressed |
| Lovastatin | Lovastatin | 46 | suppressed |
| Ezetimibe | Ezetimibe | 44 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 44 | 13 |
| Ondansetron Odt | Ondansetron | 44 | 36 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 42 | suppressed |
| Chlorthalidone | Chlorthalidone | 41 | suppressed |
| Jardiance | Empagliflozin | 41 | suppressed |
| Januvia | Sitagliptin Phosphate | 40 | suppressed |
| Loperamide | Loperamide Hcl | 40 | 26 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 40 | suppressed |
| Aripiprazole | Aripiprazole | 39 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 39 | suppressed |
| Bupropion Xl | Bupropion Hcl | 35 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 35 | 26 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 35 | 12 |
| Lamotrigine | Lamotrigine | 34 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 34 | 14 |
| Brimonidine Tartrate | Brimonidine Tartrate | 33 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 32 | suppressed |
| Primidone | Primidone | 32 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 31 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 30 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 30 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 30 | suppressed |
| Glipizide | Glipizide | 30 | suppressed |
| Digoxin | Digoxin | 29 | suppressed |
| Nystatin | Nystatin | 29 | 19 |
| Solifenacin Succinate | Solifenacin Succinate | 29 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 28 | suppressed |
| Fluconazole | Fluconazole | 28 | 21 |
| Pioglitazone Hcl | Pioglitazone Hcl | 28 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 28 | 12 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 27 | 19 |
| Ranolazine Er | Ranolazine | 27 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 26 | suppressed |
| Glipizide Er | Glipizide | 26 | suppressed |
| Telmisartan | Telmisartan | 26 | suppressed |
| Azithromycin | Azithromycin | 25 | 24 |
| Doxepin Hcl | Doxepin Hcl | 25 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 25 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 25 | suppressed |
| Topiramate | Topiramate | 25 | suppressed |
| Valsartan | Valsartan | 25 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 24 | suppressed |
| Baclofen | Baclofen | 23 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 23 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 23 | suppressed |
| Calcitriol | Calcitriol | 22 | suppressed |
| Celecoxib | Celecoxib | 22 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 22 | suppressed |
| Prednisone | Prednisone | 22 | suppressed |
| Pregabalin | Pregabalin | 22 | suppressed |
| Torsemide | Torsemide | 22 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 21 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 21 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 21 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 20 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 20 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 20 | suppressed |
| Folic Acid | Folic Acid | 19 | suppressed |
| Irbesartan | Irbesartan | 19 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 19 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 19 | 12 |
| Symbicort | Budesonide/Formoterol Fumarate | 19 | suppressed |
| Temazepam | Temazepam | 19 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 18 | 12 |
| Diltiazem Hcl | Diltiazem Hcl | 18 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 18 | 16 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 18 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 18 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 18 | suppressed |
| Namzaric | Memantine Hcl/Donepezil Hcl | 18 | suppressed |
| Bumetanide | Bumetanide | 17 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 17 | suppressed |
| Diltiazem 24hr Er (La) | Diltiazem Hcl | 17 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 17 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 17 | suppressed |
| Metolazone | Metolazone | 17 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 17 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 17 | suppressed |
| Estradiol | Estradiol | 16 | suppressed |
| Fentanyl | Fentanyl | 16 | suppressed |
| Fluorometholone | Fluorometholone | 16 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 16 | suppressed |
| Trospium Chloride | Trospium Chloride | 16 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 16 | suppressed |
| Armour Thyroid | Thyroid,pork | 15 | suppressed |
| Carbamazepine | Carbamazepine | 15 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 15 | suppressed |
| Letrozole | Letrozole | 15 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 15 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 14 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 14 | suppressed |
| Mirabegron Er | Mirabegron | 14 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 14 | 12 |
| Valproic Acid | Valproic Acid | 14 | suppressed |
| Dorzolamide Hcl | Dorzolamide Hcl | 13 | suppressed |
| Leflunomide | Leflunomide | 13 | suppressed |
| Lidocaine | Lidocaine | 13 | suppressed |
| Mesalamine Er | Mesalamine | 13 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 13 | suppressed |
| Dabigatran Etexilate | Dabigatran Etexilate Mesylate | 12 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 12 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 12 | suppressed |
| Nystop | Nystatin | 12 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 12 | suppressed |
| Ramipril | Ramipril | 12 | suppressed |
| Rivastigmine | Rivastigmine | 12 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 12 | suppressed |
| Trimethoprim | Trimethoprim | 12 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 12 | suppressed |
| Entresto | Sacubitril/Valsartan | 11 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 11 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 11 | suppressed |
| Levofloxacin | Levofloxacin | 11 | suppressed |
| Mycophenolate Mofetil | Mycophenolate Mofetil | 11 | suppressed |
| Tradjenta | Linagliptin | 11 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $285.55 · 4 records | Stryker Corporation | INFINITY ADAPTIS, INLYTA, PADCEV, TRIATHLON, Veozah | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with Astellas Pharma US Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error